Sin conexión a internet: se muestra la versión guardada de la página.

Bristol-Myers Squ…

USUSD
← Al Screener

Bristol-Myers Squibb Company (LSE:0R1F) — Drug Manufacturers - General. Número de bolsas en las que cotizan las acciones de la empresa: 6. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.

Sobre la Empresa

Sitio Web
bms.com
Relaciones con los Inversores
bms.com/investors.html
Sector
Healthcare · Drug Manufacturers - General
Sede Central
PRINCETON, United States
Consejero Delegado
Christopher S. Boerner
Empleados
32 500
Fundada
1989
Acciones en Circulación
2.04 mil M a 2026-07-22
Capital Flotante
2.04 mil M
Capitalización Bursátil
128.41 mil M USD
Insiders
0.1%
Inversores Institucionales
84.87%
Industria (SIC)
Pharmaceutical Preparations
Forma Jurídica
XTIQ
ISIN
US1101221083
LEI
HLYYNH7UQUORYSJQCN42
Ratio de Reparto
54.9%
FCF
11.4 mil M USD
Pagos / FCF
45%
Deuda
43.9 mil M USD
3.1 a. de FCF
Racha de Dividendos
54 a.
Beneficios, FCF y dividendos pagados — para los 12 meses hasta 30.06.2026 (el último informe de la compañía).
NAV
10.93 USD
Fecha del Balance30.06.2026
Activos87.6 mil M USD
− Pasivos65.3 mil M USD
= NAV (patrimonio de los accionistas de la empresa)22.3 mil M USD
− Fondo de Comercio21.7 mil M USD
− Activos Intangibles17.4 mil M USD
= NAV Tangible−16.8 mil M USD
Acciones2 042 714 656
NAV por Acción10.93 USD
NAV Tangible por Acción−8.23 USD
Historial del NAV
Fecha del BalanceNAVNAV por Acción
30.06.202622.3 mil M USD10.93 USD
31.03.202620.1 mil M USD9.83 USD
31.12.202518.5 mil M USD9.07 USD
30.09.202518.6 mil M USD9.11 USD
30.06.202517.4 mil M USD8.57 USD
31.03.202517.4 mil M USD8.54 USD
31.12.202416.3 mil M USD8.05 USD
30.09.202417.1 mil M USD8.45 USD
Descripción

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

anuncio

Bolsas y Tickers

BolsaTickerMonedaPrecioTipo
US USA StocksBMY principalUSD60.57 +2.18%acciones ordinarias
LSE London Stock Exchange0R1F IOBGBP—acciones ordinarias
MI Borsa Italiana (Milan)1BMY secundariaEUR54.3 -1.08%acciones ordinarias
MX Mexican Stock ExchangeBMY secundariaMXN1 130 +7.93%acciones ordinarias
VI Vienna Stock ExchangeBMYS secundariaEUR52.98 +0.34%acciones ordinarias
XETRA XetraBRM secundariaEUR53.04 +0.89%acciones ordinarias

Precio en 3 Meses

día alcista día bajista fecha ex-dividendo fecha de pagoPasa el cursor / toca un día — precios de apertura, cierre, máximo y mínimo

Dividendos

Por año, US:BMY: 2.52 USD (4 pagos)

Bristol-Myers Squibb Company (BMY) paga dividendos trimestralmente. Por año (12 meses hasta e incluyendo el último pago anunciado): 2.52 USD por acción (pagos: 4). Eso representa aproximadamente el 4.16% del precio actual de la acción. Según el historial de pagos, se espera la próxima fecha ex-dividendo alrededor de 01.01.2027. Historial de dividendos ininterrumpido: 54 años.

Fecha ExPagoImporte%TipoTicker
2026-10-022026-11-020.6300 USD1.0/4.1 %trimestralUS:BMY
2026-07-022026-08-030.6300 USD1.1/4.4 %trimestralUS:BMY
2026-04-022026-05-010.6300 USD1.0/4.0 %trimestralUS:BMY
2026-01-022026-02-020.6300 USD1.2/4.6 %trimestralUS:BMY
2025-10-032025-11-030.6200 USD1.4/5.4 %trimestralUS:BMY
2025-07-032025-08-010.6200 USD1.3/5.2 %trimestralUS:BMY
2025-04-042025-05-010.6200 USD1.1/4.2 %trimestralUS:BMY
2025-01-032025-02-030.6200 USD1.1/4.3 %trimestralUS:BMY
2024-10-042024-11-010.6000 USD1.0/4.0 %trimestralUS:BMY
2024-07-052024-08-010.6000 USD1.0/3.9 %trimestralUS:BMY
2024-04-042024-05-010.6000 USD1.0/3.9 %trimestralUS:BMY
2024-01-042024-02-010.6000 USD1.0/3.8 %trimestralUS:BMY
2023-10-052023-11-010.5700 USD0.9/3.8 %trimestralUS:BMY
2023-07-062023-08-010.5700 USD0.9/3.7 %trimestralUS:BMY
2023-04-062023-05-010.5700 USD0.9/3.7 %trimestralUS:BMY
2023-01-052023-02-010.5700 USD0.9/3.6 %trimestralUS:BMY
2022-10-062022-11-010.5400 USD0.9/3.6 %trimestralUS:BMY
2022-06-302022-08-010.5400 USD0.9/2.7 %trimestralUS:BMY
2022-03-312022-05-020.5400 USD0.9/1.8 %trimestralUS:BMY
2022-01-062022-02-010.5400 USD0.9/0.9 %trimestralUS:BMY

Principales Accionistas

TitularParticipaciónAccionesFecha del Informe
Blackrock Inc.8.83%180.38 M2026-06-30
Vanguard Capital Managem…6.53%133.34 M2026-06-30
State Street Corporation5.01%102.41 M2026-06-30
JPMORGAN CHASE & CO3.51%71.71 M2026-06-30
Charles Schwab Investmen…3.31%67.6 M2026-06-30
VANGUARD INDEX FUNDS-Van…3.17%64.83 M2026-06-30
Geode Capital Management…2.76%56.44 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.59%52.92 M2026-06-30
SCHWAB STRATEGIC TRUST-S…2.38%48.64 M2026-05-31
Vanguard Portfolio Manag…2.29%46.87 M2026-06-30
NORGES BANK1.8%36.87 M2026-06-30
Bank of America Corporat…1.67%34.05 M2026-06-30
Price (T.Rowe) Associate…1.55%31.71 M2026-06-30
iShares Trust-iShares Co…1.35%27.55 M2026-08-31
Fidelity Concord Street…1.29%26.41 M2026-07-31
SPDR S&P 500 ETF TRUST-S…1.22%24.96 M2026-08-31
VANGUARD INDEX FUNDS-Van…0.95%19.44 M2026-06-30
SELECT SECTOR SPDR TRT-S…0.72%14.68 M2026-08-31
VANGUARD CHESTER FUNDS-V…0.7%14.29 M2026-06-30
VANGUARD INSTITUTIONAL I…0.54%11.09 M2026-06-30
LEUNG SANDRA (General Co…≈0.02%465 3742025-03-10
ELKINS DAVID VINCENT (Ch…≈0.01%159 5422026-04-01
BOERNER CHRISTOPHER S (C…≈0.01%146 8902026-03-10
HIRAWAT SAMIT (Officer)≈0%83 5132025-04-25
HALLER JULIA A (Director…≈0%34 0792026-06-15
MEYERS GREGORY SCOTT (Ch…≈0%30 3612026-03-10
LENKOWSKY ADAM (Officer)≈0%28 6772026-05-01
SHANAHAN KARIN (Officer)≈0%27 3452026-04-01
PLENGE ROBERT M (Officer…≈0%24 7542026-03-10
MASSACESI CRISTIAN (Offi…≈0%18 7482026-09-09